Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

@article{Urtishak2013PotentOC,
  title={Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.},
  author={Karen A Urtishak and Alena Y. Z. Edwards and Li-San Wang and Amanda Hudome and Blaine W Robinson and Jeffrey S. Barrett and Kajia Cao and Lori A Cory and Jonni S. Moore and Andrew D Bantly and Qian-chun Yu and I-Ming Chen and Susan R. Atlas and Cheryl L. Willman and Mondira Kundu and Andrew J. Carroll and Nyla A. Heerema and Meenakshi Devidas and Joanne M. Hilden and ZoAnn Dreyer and Stephen P Hunger and Gregory H. Reaman and Carolyn A. Felix},
  journal={Blood},
  year={2013},
  volume={121 14},
  pages={2689-703}
}
Survival in infants younger than 1 year who have acute lymphoblastic leukemia (ALL) is inferior whether MLL is rearranged (R) or germline (G). MLL translocations confer chemotherapy resistance, and infants experience excess complications. We characterized in vitro sensitivity to the pan-antiapoptotic BCL-2 family inhibitor obatoclax mesylate in diagnostic leukemia cells from 54 infants with ALL/bilineal acute leukemia because of the role of prosurvival BCL-2 proteins in resistance, their… CONTINUE READING
26 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…